NEW YORK, Nov. 14 (GenomeWeb News) - Open Biosystems has obtained an exclusive license to use Tranzyme Pharma's trans-lentiviral gene-expression technology, the company said today.
Under the agreement, Open Biosystems can develop and commercialize products based on the gene-expression technology. Open Biosystems will assume Tranzyme's Birmingham, Ala., operations and expand lentiviral-based product development and production.
Tranzyme will receive minimum annual payments and royalties on sales of products and services that depend on its technology, Open Biosystems said. The amount for the minimum payments was not disclosed.
Tranzyme's human-based trans-lentiviral gene expression technology can be used in neuroscience research, and Open Biosystems will provide proprietary research reagents and services based on lentiviral vectors.